April 1986

Portacaval Shunt as Treatment for Glycogenosis Ib-Reply

Author Affiliations

Department of Pediatrics University of Colorado School of Medicine Denver, CO 80262

Am J Dis Child. 1986;140(4):324. doi:10.1001/archpedi.1986.02140180058012

In Reply.—Corbeel et al1 have suggested that portacaval anastomosis be considered as a primary mode of therapy to resolve neutropenia and neutrophil dysfunction on the basis of clinical experience with a patient previously described. However, in at least one other patient, a portacaval shunt operation did not reverse the neutropenia or infections2; and, indeed, the patient described by Corbeel et al had neutropenia on at least three occasions after the portacaval anastomosis.1 Furthermore, the effect of portosystemic shunting in this patient could not be completely appreciated since granulocyte dysfunction prior to surgery could not be completely documented. Finally, platelet dysfunction in Corbeel and colleagues' patient normalized in response to continuous gastric feeding for three weeks, not the shunt procedure itself. Although increases in leukocyte counts are seen in other disorders after shunting, there is little experience in glycogenosis lb to support its use routinely as a

First Page Preview View Large
First page PDF preview
First page PDF preview